-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, when Shanghai Pharmaceutical was surveyed by investors, it said that the company's clinical applications have been accepted and entered the clinical research stage of the new drug pipeline has 50, including 42 innovative drugs and 8 improved new drugs
.
Of the innovative drug pipelines, 6 are in critical research or clinical phase
III.
Many varieties of innovative drug pipelines have made progress in stages, and the R&D pipelines cover other core treatment areas
such as anti-tumor, autoimmune, systemic anti-infection, psychoneurological, vaccine, and cardiovascular.
.
Of the innovative drug pipelines, 6 are in critical research or clinical phase
III.
Many varieties of innovative drug pipelines have made progress in stages, and the R&D pipelines cover other core treatment areas
such as anti-tumor, autoimmune, systemic anti-infection, psychoneurological, vaccine, and cardiovascular.
Shanghai Pharmaceutical's total R&D investment in 2021 will reach 2.
503 billion yuan, a three-year compound increase of 21.
69%, accounting for 9.
97% of industrial sales revenue; Among them, the research and development expenditure was 1.
987 billion yuan, an increase of 23.
26%
in three years.
In recent years, under the guidance of favorable policies and market demand, China's biomedical industry has entered the "fast lane" of development, and a series of new products and services have provided new impetus
for ensuring people's life and health.
Pharmaceutical enterprises represented by Shanghai Pharmaceutical have accelerated the pace of transformation, continuously laid out innovative drug research and development, and promoted the important force
of biomedical innovation and development.
503 billion yuan, a three-year compound increase of 21.
69%, accounting for 9.
97% of industrial sales revenue; Among them, the research and development expenditure was 1.
987 billion yuan, an increase of 23.
26%
in three years.
In recent years, under the guidance of favorable policies and market demand, China's biomedical industry has entered the "fast lane" of development, and a series of new products and services have provided new impetus
for ensuring people's life and health.
Pharmaceutical enterprises represented by Shanghai Pharmaceutical have accelerated the pace of transformation, continuously laid out innovative drug research and development, and promoted the important force
of biomedical innovation and development.
Continue to increase R&D investment and take root in the innovation and development track
Innovation in the pharmaceutical market is an eternal topic
for the high-quality development of the pharmaceutical industry.
For Shanghai Medicine, "innovation" is a high-frequency word that has been constantly mentioned in recent years, placed in the first place of the four major development strategies of Shanghai Medicine, and is one of
the core values that the company has been practicing.
for the high-quality development of the pharmaceutical industry.
For Shanghai Medicine, "innovation" is a high-frequency word that has been constantly mentioned in recent years, placed in the first place of the four major development strategies of Shanghai Medicine, and is one of
the core values that the company has been practicing.
As early as 2019, Shanghai Pharmaceutical established the strategic goal of "building an international leading pharmaceutical company driven by scientific and technological innovation", and issued an innovation development strategy and action outline, focusing on using innovation to activate the new genes
of Shanghai Medicine.
Shanghai Pharmaceutical adheres to the principle of empowering the high-quality development of the pharmaceutical industry with scientific and technological innovation, and strives to promote the achievements of pharmaceutical innovation to better serve people's life and health
.
of Shanghai Medicine.
Shanghai Pharmaceutical adheres to the principle of empowering the high-quality development of the pharmaceutical industry with scientific and technological innovation, and strives to promote the achievements of pharmaceutical innovation to better serve people's life and health
.
It is understood that Shanghai Pharmaceutical has continued to build a product chain that meets the enjoyment, affordability and clinical advantages of the broad masses of the people through various ways such as anti-tumor, autoimmunity, systemic anti-infection, psychoneurological, vaccine, cardiovascular and microecology, etc.
, and has made milestone progress
in focusing on research/introduction of new drugs.
, and has made milestone progress
in focusing on research/introduction of new drugs.
Shanghai Pharmaceutical focuses on the development of therapeutic antibodies and ADCs, actively lays out oncolytic viruses, cell therapy and other directions, and 42 innovative drugs and 8 improved new drugs in the new drug pipeline of 50 research projects
.
Among the innovative drug pipelines, 6 have been in the critical research or clinical phase III stage, of which the new anti-tumor drugs I022, I036, diabetic nephropathy new drugs I001 and stroke new drugs I037 and other innovative drug pipelines have made significant stage progress, B013I injection has obtained the approval notice of phase II/III clinical trials, and phase II clinical trials
will be launched in the near future.
.
Among the innovative drug pipelines, 6 have been in the critical research or clinical phase III stage, of which the new anti-tumor drugs I022, I036, diabetic nephropathy new drugs I001 and stroke new drugs I037 and other innovative drug pipelines have made significant stage progress, B013I injection has obtained the approval notice of phase II/III clinical trials, and phase II clinical trials
will be launched in the near future.
For the form of innovation, Zhou Jun, president of SIIC Group and chairman of Shanghai Pharmaceutical, believes that "or independent research and development, or seeking internal and external cooperation, the innovative model can be eclectic
.
" "Shanghai Pharmaceutical has always embraced innovation with an open mind and constantly improved its own innovation ecosystem
.
The introduction of Guizhou Shengnuostat acid new drug X842, the cooperation with South Korea's KoBioLabs company to treat a variety of system-free diseases of high-potential new drug project, and the Russian BIOCAD joint venture to establish Bokang company new drug clinical registration has made progress, and the new acute stroke drug cooperated with Suncheon Pharmaceutical in Taiwan has completed Phase I clinical trials
.
.
" "Shanghai Pharmaceutical has always embraced innovation with an open mind and constantly improved its own innovation ecosystem
.
The introduction of Guizhou Shengnuostat acid new drug X842, the cooperation with South Korea's KoBioLabs company to treat a variety of system-free diseases of high-potential new drug project, and the Russian BIOCAD joint venture to establish Bokang company new drug clinical registration has made progress, and the new acute stroke drug cooperated with Suncheon Pharmaceutical in Taiwan has completed Phase I clinical trials
.
Stimulate the innovation vitality of state-owned enterprises and pursue valuable innovation
Shanghai Pharmaceutical firmly believes that the core of the innovation ability of state-owned enterprises is the innovation of institutional mechanisms, and should play the leading role of state-owned enterprises and stimulate the vitality
of innovation through the "troika" of governance mechanism, employment mechanism and incentive mechanism.
of innovation through the "troika" of governance mechanism, employment mechanism and incentive mechanism.
"Talent development stimulates innovation power" is the concept that Shanghai Pharmaceutical has always adhered to
.
Ge Dawei, vice chairman of SIIC Group, secretary of the party committee and vice chairman of Shanghai Pharmaceutical Group, believes that it is necessary to continue to expand the team of innovative talents, improve the quality and improve the structure, do a good job in the selection of leading talents, scientific and technological personnel and technical experts, and effectively revitalize talent resources and increase innovation incentives
.
.
Ge Dawei, vice chairman of SIIC Group, secretary of the party committee and vice chairman of Shanghai Pharmaceutical Group, believes that it is necessary to continue to expand the team of innovative talents, improve the quality and improve the structure, do a good job in the selection of leading talents, scientific and technological personnel and technical experts, and effectively revitalize talent resources and increase innovation incentives
.
By actively improving the market-oriented selection and employment mechanism, Shanghai Pharmaceutical has increased the introduction of leading talents, high-end R&D innovation talents and international management talents, and effectively stimulated the innovation vitality
of enterprises by continuously promoting the reform of the incentive mechanism of selection, employment, education and assessment.
of enterprises by continuously promoting the reform of the incentive mechanism of selection, employment, education and assessment.
In 2020, the optimization of the R&D compensation system and the medium- and long-term incentive plan of the drug will be assessed according to the listing time point of the R&D project, the quality of the project, the milestone goal, etc.
, and the R&D personnel will be given a variety of incentive methods such as project follow-up investment and the commission of the transformation of scientific research results to achieve the benefit sharing
of value appreciation.
In addition, as an important measure for Shanghai Pharmaceutical to implement the "Double Hundred Action", Shanghai Pharmaceutical launched an equity incentive plan in 2019, granting 25.
6 million stock options to 210 core personnel, achieving a breakthrough
in equity incentives from 0 to 1.
, and the R&D personnel will be given a variety of incentive methods such as project follow-up investment and the commission of the transformation of scientific research results to achieve the benefit sharing
of value appreciation.
In addition, as an important measure for Shanghai Pharmaceutical to implement the "Double Hundred Action", Shanghai Pharmaceutical launched an equity incentive plan in 2019, granting 25.
6 million stock options to 210 core personnel, achieving a breakthrough
in equity incentives from 0 to 1.
The grand proposition of "innovation" will require more specific requirements when it lands in enterprises, and Shanghai Pharmaceutical strives to create value through innovation and seek changes
that are truly valuable to the environment and people.
The party building work that keeps pace with the times, the market-oriented operation mechanism and innovation mechanism that is continuously optimized, and the talent assessment and incentive mechanism that is constantly deepened are the embodiment of "reform" and "innovation" in business strategy, and have planted good genes
for the growth of Shanghai Medicine.
that are truly valuable to the environment and people.
The party building work that keeps pace with the times, the market-oriented operation mechanism and innovation mechanism that is continuously optimized, and the talent assessment and incentive mechanism that is constantly deepened are the embodiment of "reform" and "innovation" in business strategy, and have planted good genes
for the growth of Shanghai Medicine.
Deepening reform and innovation has also enabled Shanghai medicine to achieve phased results
.
In the first half of 2022, the company achieved operating income of 111.
707 billion yuan, an increase of 6.
15% year-on-year, and its traditional Chinese medicine industry achieved revenue of 13.
050 billion yuan, an increase of 3.
56% year-on-year; Pharmaceutical business achieved revenue of 98.
657 billion yuan, an increase of 6.
50% year-on-year, of which the company's equipment, big health and other non-pharmaceutical business sales of about 16.
7 billion, an increase of about 55%.
.
In the first half of 2022, the company achieved operating income of 111.
707 billion yuan, an increase of 6.
15% year-on-year, and its traditional Chinese medicine industry achieved revenue of 13.
050 billion yuan, an increase of 3.
56% year-on-year; Pharmaceutical business achieved revenue of 98.
657 billion yuan, an increase of 6.
50% year-on-year, of which the company's equipment, big health and other non-pharmaceutical business sales of about 16.
7 billion, an increase of about 55%.
Build an industrial innovation platform to accelerate the landing of innovative achievements
Gathering resources, building platforms, and selecting talents are the "combination fists
" for optimizing pharmaceutical innovation.
Drug research and development of original innovation in the pharmaceutical field is a high-risk, long-term and costly project, which not only requires strong basic scientific research investment and facility construction, but also needs to improve the innovation relay transformation mechanism
from basic research to applied research and industrial transformation.
" for optimizing pharmaceutical innovation.
Drug research and development of original innovation in the pharmaceutical field is a high-risk, long-term and costly project, which not only requires strong basic scientific research investment and facility construction, but also needs to improve the innovation relay transformation mechanism
from basic research to applied research and industrial transformation.
On the basis of the existing R&D platform, Shanghai Pharmaceutical continues to improve the construction of domestic and foreign R&D platforms, accelerates the embedding of global innovation chains and value chains, and establishes an open and diversified innovation ecosystem
.
Through the integration of resources, we continue to increase investment in basic research, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, and jointly build an innovation platform with universities, governments and other entities, focus on industrial cultivation, and accelerate the transformation
of innovative achievements.
.
Through the integration of resources, we continue to increase investment in basic research, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, and jointly build an innovation platform with universities, governments and other entities, focus on industrial cultivation, and accelerate the transformation
of innovative achievements.
In order to build a leading open R&D public service platform and incubation platform in China, Shanghai Pharmaceutical undertook the municipal major project biomedical industry innovation base project, which is located in the hinterland of Shanghai Zhangjiang Hi-Tech Park, where the biomedical industry is concentrated, mainly focusing on therapeutic antibodies, cell therapy, microecology, gene therapy and other fields, with the goal of building a leading domestic biomedical industry base integrating the three functions of "new R&D center, innovation incubation platform, pilot test and industrialization platform"
。
。
In order to better enhance the effectiveness of innovation, Shanghai Medicine, together with Shanghai Jiao Tong University School of Medicine, the Molecular Cell Innovation Center of the Chinese Academy of Sciences, Fudan University and other institutions, established the Shanghai Biomedical Frontier Industry Innovation Center to gather cutting-edge scientific research forces, adopt market-oriented operation methods, closely follow the whole process of new drug research and development, and promote the original innovation
of Chinese biomedicine.
of Chinese biomedicine.
Shanghai Pharmaceutical has always adhered to the drive of scientific and technological innovation, and strives to build a leading pharmaceutical enterprise in China with international competitiveness, while accelerating its own development, fully supporting and serving the construction and high-quality development of Shanghai's biomedical industry innovation highland, and giving play to the role of
industry driving and leadership.
industry driving and leadership.
It is reported that during the "14th Five-Year Plan" period, Shanghai Pharmaceutical will vigorously enhance the leading role of the biomedical industry, while insisting on expanding and strengthening its own business, relying on its comprehensive advantages in research and development, pilot test, clinical trial research, commercial operation, market promotion, etc.
, to drive the innovation and development of a number of pharmaceutical enterprises in the city, and strive to become the integrator of the city's biomedical innovation resources and the promoter
of the development of the biomedical industry.
, to drive the innovation and development of a number of pharmaceutical enterprises in the city, and strive to become the integrator of the city's biomedical innovation resources and the promoter
of the development of the biomedical industry.
Recently, when Shanghai Pharmaceutical was surveyed by investors, it said that the company's clinical applications have been accepted and entered the clinical research stage of the new drug pipeline has 50, including 42 innovative drugs and 8 improved new drugs
.
Of the innovative drug pipelines, 6 are in critical research or clinical phase
III.
Many varieties of innovative drug pipelines have made progress in stages, and the R&D pipelines cover other core treatment areas
such as anti-tumor, autoimmune, systemic anti-infection, psychoneurological, vaccine, and cardiovascular.
.
Of the innovative drug pipelines, 6 are in critical research or clinical phase
III.
Many varieties of innovative drug pipelines have made progress in stages, and the R&D pipelines cover other core treatment areas
such as anti-tumor, autoimmune, systemic anti-infection, psychoneurological, vaccine, and cardiovascular.
Shanghai Pharmaceutical's total R&D investment in 2021 will reach 2.
503 billion yuan, a three-year compound increase of 21.
69%, accounting for 9.
97% of industrial sales revenue; Among them, the research and development expenditure was 1.
987 billion yuan, an increase of 23.
26%
in three years.
In recent years, under the guidance of favorable policies and market demand, China's biomedical industry has entered the "fast lane" of development, and a series of new products and services have provided new impetus
for ensuring people's life and health.
Pharmaceutical enterprises represented by Shanghai Pharmaceutical have accelerated the pace of transformation, continuously laid out innovative drug research and development, and promoted the important force
of biomedical innovation and development.
503 billion yuan, a three-year compound increase of 21.
69%, accounting for 9.
97% of industrial sales revenue; Among them, the research and development expenditure was 1.
987 billion yuan, an increase of 23.
26%
in three years.
In recent years, under the guidance of favorable policies and market demand, China's biomedical industry has entered the "fast lane" of development, and a series of new products and services have provided new impetus
for ensuring people's life and health.
Pharmaceutical enterprises represented by Shanghai Pharmaceutical have accelerated the pace of transformation, continuously laid out innovative drug research and development, and promoted the important force
of biomedical innovation and development.
Continue to increase R&D investment and take root in the innovation and development track
Continue to increase R&D investment and take root in the innovation and development track Innovation in the pharmaceutical market is an eternal topic
for the high-quality development of the pharmaceutical industry.
For Shanghai Medicine, "innovation" is a high-frequency word that has been constantly mentioned in recent years, placed in the first place of the four major development strategies of Shanghai Medicine, and is one of
the core values that the company has been practicing.
for the high-quality development of the pharmaceutical industry.
For Shanghai Medicine, "innovation" is a high-frequency word that has been constantly mentioned in recent years, placed in the first place of the four major development strategies of Shanghai Medicine, and is one of
the core values that the company has been practicing.
As early as 2019, Shanghai Pharmaceutical established the strategic goal of "building an international leading pharmaceutical company driven by scientific and technological innovation", and issued an innovation development strategy and action outline, focusing on using innovation to activate the new genes
of Shanghai Medicine.
Shanghai Pharmaceutical adheres to the principle of empowering the high-quality development of the pharmaceutical industry with scientific and technological innovation, and strives to promote the achievements of pharmaceutical innovation to better serve people's life and health
.
of Shanghai Medicine.
Shanghai Pharmaceutical adheres to the principle of empowering the high-quality development of the pharmaceutical industry with scientific and technological innovation, and strives to promote the achievements of pharmaceutical innovation to better serve people's life and health
.
It is understood that Shanghai Pharmaceutical has continued to build a product chain that meets the enjoyment, affordability and clinical advantages of the broad masses of the people through various ways such as anti-tumor, autoimmunity, systemic anti-infection, psychoneurological, vaccine, cardiovascular and microecology, etc.
, and has made milestone progress
in focusing on research/introduction of new drugs.
, and has made milestone progress
in focusing on research/introduction of new drugs.
Shanghai Pharmaceutical focuses on the development of therapeutic antibodies and ADCs, actively lays out oncolytic viruses, cell therapy and other directions, and 42 innovative drugs and 8 improved new drugs in the new drug pipeline of 50 research projects
.
Among the innovative drug pipelines, 6 have been in the critical research or clinical phase III stage, of which the new anti-tumor drugs I022, I036, diabetic nephropathy new drugs I001 and stroke new drugs I037 and other innovative drug pipelines have made significant stage progress, B013I injection has obtained the approval notice of phase II/III clinical trials, and phase II clinical trials
will be launched in the near future.
.
Among the innovative drug pipelines, 6 have been in the critical research or clinical phase III stage, of which the new anti-tumor drugs I022, I036, diabetic nephropathy new drugs I001 and stroke new drugs I037 and other innovative drug pipelines have made significant stage progress, B013I injection has obtained the approval notice of phase II/III clinical trials, and phase II clinical trials
will be launched in the near future.
For the form of innovation, Zhou Jun, president of SIIC Group and chairman of Shanghai Pharmaceutical, believes that "or independent research and development, or seeking internal and external cooperation, the innovative model can be eclectic
.
" "Shanghai Pharmaceutical has always embraced innovation with an open mind and constantly improved its own innovation ecosystem
.
The introduction of Guizhou Shengnuostat acid new drug X842, the cooperation with South Korea's KoBioLabs company to treat a variety of system-free diseases of high-potential new drug project, and the Russian BIOCAD joint venture to establish Bokang company new drug clinical registration has made progress, and the new acute stroke drug cooperated with Suncheon Pharmaceutical in Taiwan has completed Phase I clinical trials
.
.
" "Shanghai Pharmaceutical has always embraced innovation with an open mind and constantly improved its own innovation ecosystem
.
The introduction of Guizhou Shengnuostat acid new drug X842, the cooperation with South Korea's KoBioLabs company to treat a variety of system-free diseases of high-potential new drug project, and the Russian BIOCAD joint venture to establish Bokang company new drug clinical registration has made progress, and the new acute stroke drug cooperated with Suncheon Pharmaceutical in Taiwan has completed Phase I clinical trials
.
Stimulate the innovation vitality of state-owned enterprises and pursue valuable innovation
Stimulate the innovation vitality of state-owned enterprises and pursue valuable innovation Shanghai Pharmaceutical firmly believes that the core of the innovation ability of state-owned enterprises is the innovation of institutional mechanisms, and should play the leading role of state-owned enterprises and stimulate the vitality
of innovation through the "troika" of governance mechanism, employment mechanism and incentive mechanism.
of innovation through the "troika" of governance mechanism, employment mechanism and incentive mechanism.
"Talent development stimulates innovation power" is the concept that Shanghai Pharmaceutical has always adhered to
.
Ge Dawei, vice chairman of SIIC Group, secretary of the party committee and vice chairman of Shanghai Pharmaceutical Group, believes that it is necessary to continue to expand the team of innovative talents, improve the quality and improve the structure, do a good job in the selection of leading talents, scientific and technological personnel and technical experts, and effectively revitalize talent resources and increase innovation incentives
.
.
Ge Dawei, vice chairman of SIIC Group, secretary of the party committee and vice chairman of Shanghai Pharmaceutical Group, believes that it is necessary to continue to expand the team of innovative talents, improve the quality and improve the structure, do a good job in the selection of leading talents, scientific and technological personnel and technical experts, and effectively revitalize talent resources and increase innovation incentives
.
By actively improving the market-oriented selection and employment mechanism, Shanghai Pharmaceutical has increased the introduction of leading talents, high-end R&D innovation talents and international management talents, and effectively stimulated the innovation vitality
of enterprises by continuously promoting the reform of the incentive mechanism of selection, employment, education and assessment.
of enterprises by continuously promoting the reform of the incentive mechanism of selection, employment, education and assessment.
In 2020, the optimization of the R&D compensation system and the medium- and long-term incentive plan of the drug will be assessed according to the listing time point of the R&D project, the quality of the project, the milestone goal, etc.
, and the R&D personnel will be given a variety of incentive methods such as project follow-up investment and the commission of the transformation of scientific research results to achieve the benefit sharing
of value appreciation.
In addition, as an important measure for Shanghai Pharmaceutical to implement the "Double Hundred Action", Shanghai Pharmaceutical launched an equity incentive plan in 2019, granting 25.
6 million stock options to 210 core personnel, achieving a breakthrough
in equity incentives from 0 to 1.
, and the R&D personnel will be given a variety of incentive methods such as project follow-up investment and the commission of the transformation of scientific research results to achieve the benefit sharing
of value appreciation.
In addition, as an important measure for Shanghai Pharmaceutical to implement the "Double Hundred Action", Shanghai Pharmaceutical launched an equity incentive plan in 2019, granting 25.
6 million stock options to 210 core personnel, achieving a breakthrough
in equity incentives from 0 to 1.
The grand proposition of "innovation" will require more specific requirements when it lands in enterprises, and Shanghai Pharmaceutical strives to create value through innovation and seek changes
that are truly valuable to the environment and people.
The party building work that keeps pace with the times, the market-oriented operation mechanism and innovation mechanism that is continuously optimized, and the talent assessment and incentive mechanism that is constantly deepened are the embodiment of "reform" and "innovation" in business strategy, and have planted good genes
for the growth of Shanghai Medicine.
that are truly valuable to the environment and people.
The party building work that keeps pace with the times, the market-oriented operation mechanism and innovation mechanism that is continuously optimized, and the talent assessment and incentive mechanism that is constantly deepened are the embodiment of "reform" and "innovation" in business strategy, and have planted good genes
for the growth of Shanghai Medicine.
Deepening reform and innovation has also enabled Shanghai medicine to achieve phased results
.
In the first half of 2022, the company achieved operating income of 111.
707 billion yuan, an increase of 6.
15% year-on-year, and its traditional Chinese medicine industry achieved revenue of 13.
050 billion yuan, an increase of 3.
56% year-on-year; Pharmaceutical business achieved revenue of 98.
657 billion yuan, an increase of 6.
50% year-on-year, of which the company's equipment, big health and other non-pharmaceutical business sales of about 16.
7 billion, an increase of about 55%.
Traditional Chinese Medicine Traditional Chinese Medicine is healthy and healthy.
In the first half of 2022, the company achieved operating income of 111.
707 billion yuan, an increase of 6.
15% year-on-year, and its traditional Chinese medicine industry achieved revenue of 13.
050 billion yuan, an increase of 3.
56% year-on-year; Pharmaceutical business achieved revenue of 98.
657 billion yuan, an increase of 6.
50% year-on-year, of which the company's equipment, big health and other non-pharmaceutical business sales of about 16.
7 billion, an increase of about 55%.
Build an industrial innovation platform to accelerate the landing of innovative achievements
Build an industrial innovation platform to accelerate the landing of innovative achievements Gathering resources, building platforms, and selecting talents are the "combination fists
" for optimizing pharmaceutical innovation.
Drug research and development of original innovation in the pharmaceutical field is a high-risk, long-term and costly project, which not only requires strong basic scientific research investment and facility construction, but also needs to improve the innovation relay transformation mechanism
from basic research to applied research and industrial transformation.
" for optimizing pharmaceutical innovation.
Drug research and development of original innovation in the pharmaceutical field is a high-risk, long-term and costly project, which not only requires strong basic scientific research investment and facility construction, but also needs to improve the innovation relay transformation mechanism
from basic research to applied research and industrial transformation.
On the basis of the existing R&D platform, Shanghai Pharmaceutical continues to improve the construction of domestic and foreign R&D platforms, accelerates the embedding of global innovation chains and value chains, and establishes an open and diversified innovation ecosystem
.
Through the integration of resources, we continue to increase investment in basic research, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, and jointly build an innovation platform with universities, governments and other entities, focus on industrial cultivation, and accelerate the transformation
of innovative achievements.
Medicines and medicines.
Through the integration of resources, we continue to increase investment in basic research, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, and jointly build an innovation platform with universities, governments and other entities, focus on industrial cultivation, and accelerate the transformation
of innovative achievements.
In order to build a leading open R&D public service platform and incubation platform in China, Shanghai Pharmaceutical undertook the municipal major project biomedical industry innovation base project, which is located in the hinterland of Shanghai Zhangjiang Hi-Tech Park, where the biomedical industry is concentrated, mainly focusing on therapeutic antibodies, cell therapy, microecology, gene therapy and other fields, with the goal of building a leading domestic biomedical industry base integrating the three functions of "new R&D center, innovation incubation platform, pilot test and industrialization platform"
。
Medicine and medicine。
In order to better enhance the effectiveness of innovation, Shanghai Medicine, together with Shanghai Jiao Tong University School of Medicine, the Molecular Cell Innovation Center of the Chinese Academy of Sciences, Fudan University and other institutions, established the Shanghai Biomedical Frontier Industry Innovation Center to gather cutting-edge scientific research forces, adopt market-oriented operation methods, closely follow the whole process of new drug research and development, and promote the original innovation
of Chinese biomedicine.
of Chinese biomedicine.
Shanghai Pharmaceutical has always adhered to the drive of scientific and technological innovation, and strives to build a leading pharmaceutical enterprise in China with international competitiveness, while accelerating its own development, fully supporting and serving the construction and high-quality development of Shanghai's biomedical industry innovation highland, and giving play to the role of
industry driving and leadership.
industry driving and leadership.
It is reported that during the "14th Five-Year Plan" period, Shanghai Pharmaceutical will vigorously enhance the leading role of the biomedical industry, while insisting on expanding and strengthening its own business, relying on its comprehensive advantages in research and development, pilot test, clinical trial research, commercial operation, market promotion, etc.
, to drive the innovation and development of a number of pharmaceutical enterprises in the city, and strive to become the integrator of the city's biomedical innovation resources and the promoter
of the development of the biomedical industry.
Enterprise enterprise , to drive the innovation and development of a number of pharmaceutical enterprises in the city, and strive to become the integrator of the city's biomedical innovation resources and the promoter
of the development of the biomedical industry.
